Semaglutide FDA approval was first granted on December 5, 2017, for the brand Ozempic
The EMA, after analyzing approximately 150 reports, found no clear evidence of linking GLP-1 receptor agonists to increased risks of suicidal thought, or self-injurious behavior
Every efficacy study (obesity, liver, muscle) used subcutaneous dosing, so injection is the route with the animal evidence behind it
[7] [9] The injection should not be administered to patients with severe hypersensitivity reactions to preservatives, if using the preserved formulation
In addition to his work with patients and practitioners at Central Drugs, Nayan is involved with the USC School of Pharmacy as a guest lecturer and faculty member
This is a common reason why many people regain the weight they lost after stopping GLP-1 medications